Whittier Trust Co. of Nevada Inc. Grows Stake in Thermo Fisher Scientific Inc. $TMO

Whittier Trust Co. of Nevada Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% during the first quarter, HoldingsChannel reports. The firm owned 57,900 shares of the medical research company’s stock after buying an additional 3,367 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Thermo Fisher Scientific were worth $28,266,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of TMO. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after buying an additional 288,296 shares during the last quarter. J. Stern & Co. LLP raised its stake in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the period. State Street Corp lifted its holdings in shares of Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after acquiring an additional 229,630 shares during the last quarter. Capital World Investors boosted its stake in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after purchasing an additional 718,669 shares during the period. Finally, Geode Capital Management LLC raised its position in Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after purchasing an additional 26,425 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TMO. Wolfe Research initiated coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a research note on Thursday, June 11th. They issued a “neutral” rating and a $510.00 target price on the stock. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $605.09.

Thermo Fisher Scientific Trading Down 0.2%

NYSE:TMO opened at $522.38 on Monday. The firm has a 50-day simple moving average of $473.17 and a 200-day simple moving average of $517.74. Thermo Fisher Scientific Inc. has a one year low of $403.36 and a one year high of $643.99. The firm has a market cap of $194.13 billion, a P/E ratio of 28.72, a P/E/G ratio of 2.32 and a beta of 0.87. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.